01
ProblemGI clinics lose hours every week rescuing established biologic patients when 6- or 12-month approvals expire, payers force a preferred infliximab switch, or a site-of-care rule changes after the patient is already on therapy.
RenewalWatch GI: biologic continuity desk for GI clinics
Idea Overview
TLDR
02
SolutionRenewalWatch GI is a narrow work queue for active IBD biologic patients. It flags expiring approvals, missing objective response proof, payer-mandated biosimilar changes, and infusion-location breaks days before the next dose is at risk.
03
Market opportunityIBD biologics is a big and growing spend category: Future Market Insights projects $63.9B in 2026 rising to $149.9B by 2036. Clinics already buy GI EHRs and prior-auth tools, but the renewal handoff is still held together with inboxes and spreadsheets.